Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2018-04-26 Earnings Release
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
Earnings Release 2018
Earnings Release Classification · 99% confidence The document is titled "DELÅRSRAPPORT JANUARI – MARS 2018" (Interim Report January – March 2018) and contains detailed financial statements, key performance indicators (KPIs) for the first quarter, management commentary, and a schedule for upcoming reports. The content is comprehensive, covering revenue, profit, cash flow, and balance sheet details for a period shorter than a full year. This structure and content clearly define it as a comprehensive financial report for an interim period, matching the definition of an Interim / Quarterly Report. Q1 2018
2018-04-26 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT JANUARY – MARCH 2018' and contains comprehensive financial statements, including a consolidated income statement, statement of comprehensive income, and statement of financial position for the specified period. It provides detailed analysis of sales, earnings, cash flow, and operational updates. It is not an announcement of a report, but the report itself, fitting the definition of an Interim/Quarterly Report. Q1 2018
2018-04-26 English
Investor Presentation 2018
Investor Presentation Classification · 99% confidence The document contains a detailed table of contents, a letter from the Chairman ('Ordföranden har ordet'), a section on 'Viktiga händelser under 2017' (Key events during 2017), extensive 'Finansiella data' (Financial data) including a five-year overview, revenue breakdowns, and future financial reporting dates. The content is comprehensive, covers the entire fiscal year (2017), and includes management discussion and analysis ('MDA' elements). The presence of detailed financial tables, a five-year summary, and the overall structure strongly indicates this is the company's main annual report, which corresponds to the 10-K filing type in the US context, or the equivalent comprehensive annual report. Although it mentions the Annual General Meeting ('ÅRSSTÄMMA') date (May 3, 2018), the bulk of the document is the financial and operational review for the preceding year (2017), making it the Annual Report (10-K) rather than just AGM material (AGM-R) or a simple announcement (RPA). The document length (282,080 chars) confirms it is a substantial report, not a brief announcement.
2018-04-12 Swedish
Annual Report 2018
Annual Report Classification · 100% confidence The document contains a comprehensive 'Statutory Administration Report', 'Financial statements', 'Accounting policies', 'Notes', 'Audit Report', and 'Corporate Governance Report'. It covers the full fiscal year 2017, providing detailed financial data, management commentary, and business highlights. It is clearly an Annual Report (10-K equivalent for a Swedish company). FY 2018
2018-04-12 English
KALLELSE TILL ÅRSSTÄMMA I KARO PHARMA AB
AGM Information Classification · 100% confidence The document is titled "KALLELSE TILL ÅRSSTÄMMA I KARO PHARMA AB" which translates to "NOTICE OF ANNUAL GENERAL MEETING IN KARO PHARMA AB". The text details the date, time, location, registration procedures, and the proposed agenda for the meeting. The agenda items explicitly cover matters typically addressed at an AGM, such as election of the chairman, approval of the annual report (item 8), decisions on profit distribution (item 10, including dividend proposals), election of the board and auditors (items 12-17), remuneration guidelines (item 18), and proposals for capital changes like a rights issue (item 19) and share repurchase authorizations (item 20), and an incentive program (item 21). This content is characteristic of a formal notice for an Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2018-04-04 Swedish
THE BOARD OF DIRECTORS OF KARO PHARMA HAS RESOLVED ON A FULLY GUARANTEED RIGHTS ISSUE SUBJECT TO APPROVAL BY THE ANNUAL GENERAL MEETING
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing that the Board of Directors of Karo Pharma has resolved on a fully guaranteed rights issue, which is subject to approval by the Annual General Meeting (AGM). It details the purpose (financing an acquisition), the structure of the rights issue, commitments from major shareholders, and an indicative timetable. This content directly relates to capital structure changes and fundraising activities. The key event is the resolution on the Rights Issue, which is a form of capital/financing activity. Therefore, the most appropriate classification is Capital/Financing Update (CAP). It is not the AGM material itself (AGM-R), nor is it a formal prospectus or registration document, but an announcement detailing the financing plan.
2018-04-04 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.